The Food and Drug Administration has announced a public workshop entitled, “Scientific Evidence in the Development of Human Cells, Tissues, and Cellular and Tissue-Based Products Subject to Premarket Approval.” [Read more…]
Understand Stem Cell Market Needs, so You Can Precisely Meet Them – with Minimal Time, Cost, and Risk
As a provider of stem cell products and technologies, you know you need to:
- Make effective product development decisions
- Sell more effectively
- Generate improved revenues
- Take market share
Without strategic guidance on which to base your actions, you’re in a difficult position. New products that don’t sell well are costly mistakes. On the other hand, repeatedly launching high-demand products and skillfully addressing the unmet needs of your clients is certain to position you as a market leader.
[Read more…]
ORIG3N and Kangstem Biotech Partner to Investigate Induced Neural Stem Cells for Disease Modeling
Boston biotech company ORIG3N has announced a collaboration with South Korea’s Kangstem Biotech in a joint effort to gain insight on the effectiveness of induced neural stem cells (iNSC) in disease modeling. As a pioneer of regenerative medicine, ORIG3N is leading the way towards the future of medicine by crowdsourcing blood samples to create the world’s largest and most diverse biorepository of stem cells.
As part of this collaboration, Kangstem Biotech will be providing iNSC’s to ORIG3N for research. This partnership between a pioneer in the biotechnology industry and one of the largest global biopharmaceutical companies is an exciting development in regenerative medicine. [Read more…]
Commence Bio Receives 1st Patent for MSC1, An Innovative Cancer Immunotherapy Platform
In major news released this week, Commence Bio announced that the company has received its first patent for MSC1. Commence Bio is a pre-clinical stage biotechnology company that is based on the concept that cancer and other inflammatory conditions can be addressed by “rebooting patients’ immune systems” with a new class of medicinal stem cells, MSC1 and MSC2.
The company is now developing a therapeutic pipeline, as well as offering research products that include MSC1 and MSC2 cells and media. The concept around which the company is based is that its proprietary “stimulated Toll-like receptor technology” programs naïve MSCs to either a more potent anti-inflammatory phenotype, or a new pro-inflammatory, anti-tumor phenotype. [Read more…]
Cell Therapy Systems (CTS™) Video Series – Translating Research into Clinical Success
Stem cell research has been in process for well over five decades, because stem cells have the unique ability to divide, replicate repeatedly, and differentiate into a wide variety of specialized cell types. Indeed, the possibilities arising from these characteristics have resulted in great commercial interest, with potential applications ranging from the use of stem cells in cell therapy, to pharmacological testing on cell-specific tissues and more.
Because the scientific community has expanded its activities involving stem cell research, there has been a growing need for high-quality cell culture products and systems. Large companies selling stem cell research products include Thermo Fisher Scientific, BD Biosciences, Merck KGaA, Miltenyi Biotec, STEMCELL Technologies, Lonza Group, Clontech (a Takara Bio Company), GE Healthcare Life Sciences, and others. [Read more…]
- « Previous Page
- 1
- …
- 289
- 290
- 291
- 292
- 293
- …
- 336
- Next Page »